Inovio Pharmaceuticals Inc (INO)

[KR_redondo]

BIO KOREA Sep. 11
Sep. 11 (Wed) 13:00~15:00
KINTEX Exhibition Center II / Rm. 310

This first session will give some perspectives including outcomes and opportunities of vaccine research and development (R & D) with new approaches and target disease. Topics will be provided on vaccine research and development for prevention of co-infection with virus and bacteria, current outcomes and perspectives about new technological approaches such as DNA vaccine, and new vaccine R & D. This session will provide understanding trends of new approaches and challenges in vaccine R & D.

· Synthetic Vaccines: DNA Vaccines
David B. Weiner, Professor, Professor of Pathology and Laboratory Medicine,University of
Pennsylvania School of Medicine

Sep. 13 (Fri)
KINTEX Exhibition Center II / Rm. 303

Nowadays, most of basic technologies originated in academia and research Instiutions. Start-up companies drive the commericialization under their development strategy and in the process, they often initiate the collaborations with other pharmaceutical company. Sharing the stories of experiences in both sides of the collaboration partners (Pharmaceutical & bioventure companies)
Session Chair
To be Updated

Speaker
· External Opportunity in Asia : Key Consideration in Early Stage Collaboration; Big Pharma
Perspective
Yuan-Hua Ding, Senior Director, External R&D Innovation(ERDI)-Asai/Pacific, Pfizer
· Licensing Case : Partnering with Big-Pharma
To be Updated
· Early Stage Opportunities in Merck : Merck Initiatives for New Target INT
To be Updated